

## ABSTRACT

10/020354

5 The present invention provides molecules, including IgGs, non-IgG  
immunoglobulins, proteins and non-protein agents, that have increased *in vivo* half-lives due  
to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having  
one or more amino acid modifications that increase the affinity of the constant domain or  
fragment for FcRn. Such proteins and molecules with increased half-lives have the  
advantage that smaller amounts and or less frequent dosing is required in the therapeutic,  
10 prophylactic or diagnostic use of such molecules.

15

20

25

30

35